Key result
A systematic review of 5 studies found lacking high-level evidence for managing AFRVR in ADHF, though one RCT showed diltiazem achieved therapeutic response in 100% of patients vs 0% with placebo.
Why the study?
Comparative effectiveness and safety data for pharmacological and nonpharmacological management of atrial fibrillation or flutter with rapid ventricular response in acute decompensated heart failure were needed.
What is the comparative effectiveness and safety of pharmacological and nonpharmacological management options for AFRVR in patients with ADHF?
Systematic Review
What is the comparative effectiveness and safety of pharmacological and nonpharmacological management options for AFRVR in patients with ADHF?
There is a significant lack of high-quality evidence to guide the effective and safe management of atrial fibrillation with rapid ventricular response in patients with acute decompensated heart failure.
Answers are grounded in this paper and cite their sources.
Evidence remains limited for AFRVR management in ADHF; leaves open optimal acute strategy.
OBJECTIVE: The objective was to evaluate the comparative effectiveness and safety of pharmacological and nonpharmacological management options for atrial fibrillation/atrial flutter with rapid ventricular response (AFRVR) in patients with acute decompensated heart failure (ADHF) in the acute care setting. METHODS: This study was a systematic review of observational studies or randomized clinical trials (RCT) of adult patients with AFRVR and concomitant ADHF in the emergency department (ED), intensive care unit, or step-down unit. The primary effectiveness outcome was successful rate or rhythm control. Safety outcomes were adverse events, such as symptomatic hypotension and venous thromboembolism. RESULTS: A total of 6577 unique articles were identified. Five studies met inclusion criteria: one RCT in the inpatient setting and four retrospective studies, two in the ED and the other three in the inpatient setting. In the RCT of diltiazem versus placebo, 22 patients (100%) in the treatment group had a therapeutic response compared to 0/15 (0%) in the placebo group, with no significant safety differences between the two groups. For three of the observational studies, data were limited. One observation study showed no difference between metoprolol and diltiazem for successful rate control, but worsening heart failure symptoms occurred more frequently in those receiving diltiazem compared to metoprolol (19 patients [33%] vs. 10 patients [15%], p = 0.019). A single study included electrical cardioversion (one patient exposed with failure to convert to sinus rhythm) as nonpharmacological management. The overall risk of bias for included studies ranged from serious to critical. Missing data and heterogeneity of definitions for effectiveness and safety outcomes precluded the combination of results for quantitative meta-analysis. CONCLUSIONS: High-level evidence to inform clinical decision making regarding effective and safe management of AFRVR in patients with ADHF in the acute care setting is lacking.
No takes yet. Share an insight, caveat, or question.
Niforatos et al. (2022) conducted a systematic review in Atrial fibrillation/atrial flutter with rapid ventricular response (AFRVR) and acute decompensated heart failure (ADHF). Pharmacological and nonpharmacological management (e.g., diltiazem, metoprolol) vs. Placebo or active comparator was evaluated on Successful rate or rhythm control. A systematic review of 5 studies found lacking high-level evidence for managing AFRVR in ADHF, though one RCT showed diltiazem achieved therapeutic response in 100% of patients vs 0% with placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: